Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

In recent years, Novartis, GSK, Pfizer and Johnson & Johnson have hived off consumer health units and bet their futures on innovative drugs emerging from their own laboratories or through licensing ...

BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and ...

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...

The Food and Drug Administration on Wednesday officially put two late-stage trials of a gene-editing treatment from Intellia Therapeutics on hold, adding more complexity to a voluntary halt the ...

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech ...

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant ...